Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy

Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet